行情

PTLA

Portola制药
PTLA
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
-4.4386
11.09
19.64
1,415,059,614.51
关于 PTLA
Portola Pharmaceuticals, Inc.是一家生物制药公司。该公司专注于为有限制或没有批准治疗选择的患者开发和销售血栓症、其他血液疾病和炎症领域的治疗方法。该公司的两个主导产品,Betrixaban和Andexanet alfa,解决在血栓症或血栓领域未满足的医疗需求。其第三个候选产品是Cerdulatinib。该公司的Syk是各种免疫细胞免疫反应的介质。该公司正在从事一个多种高选择性Syk抑制剂相关项目,其中一种通过与Ora Inc.合作进行。其Betrixaban是一种每日一次的口服因子Xa抑制剂。其Andexanet alfa是一种重组蛋白罕见药,旨在降低用fXa抑制剂治疗患者的抗凝血活性。该公司正在开发治疗血液疾病和炎症的口服激酶抑制剂。
展开

PTLA 新闻

更多
Alexion completes acquisition of Portola Pharma; SEC charges with FCPA violations
Seeking Alpha - Article · 07/02 13:29
Portola Pharmaceuticals Inc (PTLA): Hedge Funds Are Cashing Out
Insider Monkey · 06/24 15:36
Rigrodsky & Long, P.A. Files Class Action Suit Against Portola Pharmaceuticals, Inc.
GlobeNewswire · 06/18 04:30
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late
Seeking Alpha - Article · 06/10 18:44
SHAREHOLDER ALERT: WeissLaw LLP Reminds QUMU, TCO, PTLA, and WLTW Shareholders About Its Ongoing Investigations
GlobeNewswire · 06/05 22:24
KLXE, TORC, TERP, and PTLA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
GlobeNewswire · 06/04 15:15
Lifshitz Law Firm, P.C. Announces Investigation of Franklin Financial Network, Inc., Mobile Mini, Inc., Portola Pharmaceuticals, Inc., resTORbio, Inc., Stemline Therapeutics, Inc., Taubman Centers, Inc. and Willis Towers Watson Public Limited Company and Wright Medical Group N.V.
PR Newswire · 05/28 15:11
Portola Pharmaceuticals Option Alert: Jan 15 $17.5 Puts Sweep (8) near the Bid: 504 @ $0.25 vs 7198 OI; Ref=$17.835
Benzinga · 05/22 14:34

热门股票

代码
价格
涨跌幅

微牛提供Portola制药(NASDAQ-PTLA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTLA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PTLA股票基本功能。